Personalized infliximab dosing for active Crohn's fistulas
Part of Digestive system clinical trials.
This study tests whether adjusting the dose of infliximab (a biologic medicine given by IV) based on drug levels in your blood works better for treating draining fistulas caused by Crohn's disease. It is for people who have not tried other biologics and whose fistulas have not healed with usual treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 19 and 80 years old.
- You have Crohn's disease with at least one draining fistula (tunnel) near your anus that leaks fluid or pus.
- You have never tried biologic medications (like Remicade, Humira, or Stelara) for your Crohn's.
- At least two standard treatments (like antibiotics, drainage, or immune-suppressing drugs) have not helped your fistula.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a more precise way to start infliximab (a Crohn’s medicine) and adjust dosing based on how your body responds. It aims to better control Crohn’s inflammation early and keep it under control.
This study measures how infliximab (a medicine that calms immune inflammation) moves through the body in children with Crohn’s disease. It mainly helps doctors understand dosing and drug levels, especially when treatment is newly starting.
This trial tests if a special stem cell treatment (called DB-3Q bmMSC-EVs) can help heal fistulas caused by Crohn's disease. It's for people who have already tried other treatments and still have actively draining fistulas.
This trial tests whether people with Crohn’s disease or ulcerative colitis who are currently well-controlled can safely use less-frequent anti-TNF medicine. It may help reduce treatment intensity while keeping inflammation under control.
This study tests if switching from a high-dose infliximab IV infusion to a daily or weekly injection under the skin works just as well. It is for people with inflammatory bowel disease who are already stable on IV infliximab.
This trial studies a combination of immune-suppressing treatments for children with Crohn’s disease that is not well controlled. It may help reduce inflammation and improve symptoms if you meet the study’s disease-activity and safety requirements.
Hear when a new Infliximab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.